ERBB2 and breast carcinoma: Intriguingly, β-catenin signaling represents a critical event for invasion and migration in a breast cancer model that overexpressed HER2 [23], and β-catenin knockdown seems to sensitize cells to anti-HER2 treatment with trastuzumab [49].